A carregar...
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2 diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current treatments are effective at reducing hyperglycaemia. GLP-1 exerts specific actions on the cardiovascular system in both healthy individual...
Na minha lista:
| Publicado no: | Cardiovasc Endocrinol Metab |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6739887/ https://ncbi.nlm.nih.gov/pubmed/31646274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000147 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|